Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News ContraFect Corporation (EM) CFRXQ

Healthcare Biotechnology
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (EXPM:CFRXQ)

ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study

GlobeNewswire October 16, 2023

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

GlobeNewswire September 19, 2023

ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

GlobeNewswire September 18, 2023

ContraFect to Present at the World Anti-Microbial Resistance Congress 2023

GlobeNewswire August 28, 2023

ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 14, 2023

ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million

GlobeNewswire June 27, 2023

ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company's Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens

GlobeNewswire June 20, 2023

ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023

GlobeNewswire June 8, 2023

ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 15, 2023
View More News ››

Opinion & Analysis (EXPM:CFRXQ)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:CFRXQ)

CFRX..... You've all been had

Again Happy Fryday !
Iseneschal - April 28, 2023

CFRX....stopped out

Cheers !
Iseneschal - April 27, 2023

CFRX....expect the unexpected

This could pop..... $2.50 target My 1st entry here at $1.93 Fingers crossed....tight stop ; )
Iseneschal - April 27, 2023

CFRX..... N.L.O.D $2.03

What can I say ? I won't say it ; )
Iseneschal - April 27, 2023

CFRX.... Just when u think it's a sideways action

It breaks support and goes lower Leopards don't change spots  Neither do Maggots
Iseneschal - April 27, 2023

CFRX.... N.L.O.D $2.12

Playin possum Mr. M????
Iseneschal - April 27, 2023
View more Bullboard ››

Pelangio Exploration Inc.

Pelangio Exploration Inc.

Pelangio Exploration Inc., a mineral exploration company, engages in the acquisition, exploration, and development of mineral ...
View More »